QQQ   416.36 (-1.67%)
AAPL   165.22 (-1.09%)
MSFT   400.51 (-0.93%)
META   483.43 (-3.66%)
GOOGL   154.21 (-1.15%)
AMZN   174.94 (-2.39%)
TSLA   148.29 (-1.09%)
NVDA   790.23 (-6.67%)
AMD   149.37 (-3.68%)
NIO   3.83 (-4.25%)
BABA   68.94 (+0.09%)
T   16.40 (+0.43%)
F   12.11 (+0.41%)
MU   107.36 (-4.08%)
GE   148.94 (-2.62%)
CGC   8.12 (+3.70%)
DIS   112.20 (-0.20%)
AMC   3.22 (+10.27%)
PFE   25.83 (+1.73%)
PYPL   62.07 (-0.05%)
XOM   119.74 (+1.03%)
QQQ   416.36 (-1.67%)
AAPL   165.22 (-1.09%)
MSFT   400.51 (-0.93%)
META   483.43 (-3.66%)
GOOGL   154.21 (-1.15%)
AMZN   174.94 (-2.39%)
TSLA   148.29 (-1.09%)
NVDA   790.23 (-6.67%)
AMD   149.37 (-3.68%)
NIO   3.83 (-4.25%)
BABA   68.94 (+0.09%)
T   16.40 (+0.43%)
F   12.11 (+0.41%)
MU   107.36 (-4.08%)
GE   148.94 (-2.62%)
CGC   8.12 (+3.70%)
DIS   112.20 (-0.20%)
AMC   3.22 (+10.27%)
PFE   25.83 (+1.73%)
PYPL   62.07 (-0.05%)
XOM   119.74 (+1.03%)
QQQ   416.36 (-1.67%)
AAPL   165.22 (-1.09%)
MSFT   400.51 (-0.93%)
META   483.43 (-3.66%)
GOOGL   154.21 (-1.15%)
AMZN   174.94 (-2.39%)
TSLA   148.29 (-1.09%)
NVDA   790.23 (-6.67%)
AMD   149.37 (-3.68%)
NIO   3.83 (-4.25%)
BABA   68.94 (+0.09%)
T   16.40 (+0.43%)
F   12.11 (+0.41%)
MU   107.36 (-4.08%)
GE   148.94 (-2.62%)
CGC   8.12 (+3.70%)
DIS   112.20 (-0.20%)
AMC   3.22 (+10.27%)
PFE   25.83 (+1.73%)
PYPL   62.07 (-0.05%)
XOM   119.74 (+1.03%)
QQQ   416.36 (-1.67%)
AAPL   165.22 (-1.09%)
MSFT   400.51 (-0.93%)
META   483.43 (-3.66%)
GOOGL   154.21 (-1.15%)
AMZN   174.94 (-2.39%)
TSLA   148.29 (-1.09%)
NVDA   790.23 (-6.67%)
AMD   149.37 (-3.68%)
NIO   3.83 (-4.25%)
BABA   68.94 (+0.09%)
T   16.40 (+0.43%)
F   12.11 (+0.41%)
MU   107.36 (-4.08%)
GE   148.94 (-2.62%)
CGC   8.12 (+3.70%)
DIS   112.20 (-0.20%)
AMC   3.22 (+10.27%)
PFE   25.83 (+1.73%)
PYPL   62.07 (-0.05%)
XOM   119.74 (+1.03%)
Free Trial
NASDAQ:NYMX

Nymox Pharmaceutical (NYMX) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)
Free NYMX Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
N/A
50-Day Range
$0.19
▼
$0.47
52-Week Range
N/A
Volume
932,700 shs
Average Volume
94,622 shs
Market Capitalization
$18.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
NYMX stock logo

About Nymox Pharmaceutical Stock (NASDAQ:NYMX)

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in various clinical trials for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert for detecting tobacco product usage; and TobacAlert for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment of Alzheimer's disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, the Bahamas.

NYMX Stock News Headlines

December 27, 2023 | markets.businessinsider.com
Nymox December 27 Message to Shareholders
December 27, 2023 | finanznachrichten.de
Nymox Pharmaceutical Corporation: Nymox December 27 Message to Shareholders
April 19, 2024 | Gold Safe Exchange (Ad)
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
November 30, 2023 | finance.yahoo.com
Nymox Reports California Court Issues Preliminary Injunction Against Defendants Lanham, Riley, Cutler and Others
November 22, 2023 | finanznachrichten.de
Nymox Pharmaceutical Corporation: $250 Million Lawsuit Filed Against AscellaHealth by Nymox Accepted and Summons Issued in California Court
November 21, 2023 | markets.businessinsider.com
$250 Million Lawsuit Filed Against AscellaHealth by Nymox Accepted and Summons Issued in California Court
November 9, 2023 | markets.businessinsider.com
Nymox Pharmaceutical Corporation Sues AscellaHealth For $250 Million
November 6, 2023 | finance.yahoo.com
The Committee to Restore Nymox Shareholder Value Provides Factual Update to Nymox Shareholders Regarding Special Meeting
April 19, 2024 | Gold Safe Exchange (Ad)
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
November 3, 2023 | financialpost.com
NYMOX REPORTS NOTICE: California Court Issued A Temporary Restraining Order Enjoining Lanham, Riley, Cutler And Their Nevada Company After Court Hearing In Santa Ana, California, November 2, 2023
October 27, 2023 | benzinga.com
Notice: Nymox Informs Its Shareholders Not to Take Calls or Participate in An Unauthorized and Improper Shareholder Meeting
October 26, 2023 | finanznachrichten.de
Nymox Pharmaceutical Corporation: Nymox Reports New NYMOZARFEX Marketing Application is Accepted For Review
October 11, 2023 | finance.yahoo.com
The Committee to Restore Nymox Shareholder Value Issues Notice of Special Meeting of Nymox Pharmaceutical Shareholders
October 6, 2023 | businesswire.com
Bahamas Supreme Court Rules in Favor of Committee to Restore Nymox Shareholder Value: Orders Shareholder Meeting, Grants Injunction Freezing CEO Shares
September 26, 2023 | finance.yahoo.com
Nymox Pharmaceutical Corporation (NYMXF)
September 25, 2023 | markets.businessinsider.com
Nymox Announces Submission of New Marketing Authorization Application Submission for NYMOZARFEX (TM) for BPH
August 29, 2023 | markets.businessinsider.com
Nymox Reports Completion of $2 Million Private Placement
July 18, 2023 | finanznachrichten.de
Nymox Pharmaceutical Corporation: Nymox Reports on U.S. Patent Issuances
July 18, 2023 | finance.yahoo.com
Nymox Reports on U.S. Patent Issuances
July 16, 2023 | venturebeat.com
The Committee to Restore Nymox Shareholder Value Soundly Rebuts Injurious Allegations Made by Nymox Pharmaceutical Corp Current Management
July 12, 2023 | finance.yahoo.com
Nymox Announces Appointment Of Patrick Doody as Vice President and Member of the Board of Directors of Nymox
July 9, 2023 | venturebeat.com
Rebuttal Letters Issued to Shareholders of NYMOX PHARMACEUTICAL CORP (“NYMX-Q”)
July 8, 2023 | finanznachrichten.de
Nymox Pharmaceutical Corporation: NYMOX Update
July 7, 2023 | financialpost.com
NYMOX Update
July 6, 2023 | investorplace.com
Why Is Nymox Pharmaceutical (NYMX) Stock Down 18% Today?
July 6, 2023 | seekingalpha.com
Nymox Pharmaceutical receives potential delisting notice from Nasdaq
July 6, 2023 | msn.com
NYMX Tanks after Receiving Delisting Notice
See More Headlines
Receive NYMX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nymox Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/14/2014
Today
4/19/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Diagnostic substances
Sub-Industry
N/A
Current Symbol
NASDAQ:NYMX
CUSIP
N/A
CIK
1018735
Web
www.nymox.com
Phone
(800) 936-9669
Fax
514-332-2227
Employees
3
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($0.04)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-6,580,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-1,589.50%
Return on Assets
-117.25%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.19
Quick Ratio
0.19

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.01) per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
90,510,000
Free Float
41,637,000
Market Cap
$18.10 million
Optionable
Optionable
Beta
0.64
Ten Starter Stocks For Beginners to Buy Now Cover
Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Dr. Paul Averback DABP (Age 72)
    M.D., Founder, Chairman, CEO & Pres
    Comp: $660k
  • Mr. Randall J. Lanham Esq. (Age 59)
    J.D., Gen. Counsel, Sec., COO & Director
    Comp: $496.45k
  • Ms. Lin Dodd
    QA and Compliance Mang.
  • Mr. Christopher R. Riley
    Chief Financial Officer

Key Competitors

View All Competitors

NYMX Stock Analysis - Frequently Asked Questions

How were Nymox Pharmaceutical's earnings last quarter?

Nymox Pharmaceutical Co. (NASDAQ:NYMX) issued its quarterly earnings data on Friday, November, 14th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter. The biopharmaceutical company earned $0.08 million during the quarter.

What other stocks do shareholders of Nymox Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nymox Pharmaceutical investors own include Quantum (QTM), Rocket Pharmaceuticals (RCKT), Biocept (BIOC), TherapeuticsMD (TXMD), Catalyst Pharmaceuticals (CPRX), MEI Pharma (MEIP), OPKO Health (OPK), Rigel Pharmaceuticals (RIGL), Synergy Pharmaceuticals (SGYP) and CTI BioPharma (CTIC).

This page (NASDAQ:NYMX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
Paradigm Press
Biden’s $374B Giveaway Into This Sector
DTI
The #1 Crypto for 2024
InvestorPlace
He Is Giving Away Bitcoin
Crypto Swap Profits
1970’s computer coder issues shocking A.I. warning
TradeSmith